Kyverna Therapeutics, Inc. (KYTX)
5.15
-0.01
(-0.19%)
USD |
NASDAQ |
Nov 04, 16:00
5.12
-0.03
(-0.58%)
After-Hours: 20:00
Kyverna Therapeutics Shareholders Equity (Quarterly) : 165.55M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 165.55M |
| March 31, 2026 | 195.58M |
| December 31, 2025 | 232.28M |
| September 30, 2025 | 151.95M |
| June 30, 2025 | 184.38M |
| March 31, 2025 | 224.01M |
| December 31, 2024 | 266.59M |
| September 30, 2024 | 302.71M |
| Date | Value |
|---|---|
| June 30, 2024 | 333.51M |
| March 31, 2024 | 360.99M |
| December 31, 2023 | 49.18M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 46.68M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 219.82M |
| Total Liabilities (Quarterly) | 54.27M |
| Debt to Equity Ratio | 0.1993 |
| Current Ratio | 9.058 |
| Net Debt Paydown Yield | -0.95% |